FDA action date September 28 for CV benefit claim for Amarin’s Vascepa

The FDA accepts for review Amarin’s (NASDAQ:AMRN) marketing application seeking a cardiovascular risk reduction benefit claim for Vascepa (icosapent ethyl). Under Priority Review status, the agency’s action date is September 28.

Shares are up 8% premarket on light volume.

https://seekingalpha.com/news/3467381-fda-action-date-september-28-cv-benefit-claim-amarins-vascepa-shares-8-percent-premarket